3️⃣5️⃣0️⃣+ attendees 😎 2️⃣6️⃣+ countries 🌏 3️⃣8️⃣+ speakers 🗣️ 3️⃣ amazing days 🤩 This is #PSMA #theranostics 🚀 This is next-gen #PrecisionOncology in Practice 🎯 This is #ProsTIC24 💪 @PeterMacCC @DrMHofman

🚀 Is 6 cycles of Lutetium-177 PSMA the limit? Definitely not! 💪 Our research in 50+ men with prostate cancer treated beyond 6 cycles shows that re-treatment can further improve outcomes. 📉 PSA ↓ >50% in 40% of patients on re-treatment. 🕒 Median overall survival: an

The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

#ASCO25 BULSSEYE Ph2 trial👉 Lu-PSMA in oligo mHSPC ▶️58 pts oHSPC, PSA DT<6, max of 5 Mets 👉 R 1:1 Lu-PSMA vs. deferred ADT ▶️1 Endpoint: PFS (without ADT) ✨Rationale: Lu-PSMA as MDT monotherapy in oligorecurrent HSPC to prolong ADT-free interval👉HR 0.07 (0.02-0.19, p<0.001)

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

This week at @PeterMacCC in the clinic: Therapy: Tb-161, Ac-225, Lu-177, Ra-223, I-131 Diagnostic: F-18, Ga-68, I-124, Tc-99m, Cr-51 Missing some our friends Zr-89, Cu-64, maybe next week @pros_tic

Congrats @ANZUPTrials #TheraP study presented #ASCO25 by Dr Aslı Munzur. Thanks to @PCFnews @bccancerfdn @TerryFoxCanada #CanadianCancerSociety @PeterMacCC @pros_tic @VanProstateCtr @VCHResearch @UBC @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @Novartis

Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair

Dear Colleagues at #ASCO25 with an exciting day today in GU Oncology We invite you to read our paper Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 https://t.co/fmUzljwMHC The 2024 Advanced Prostate Cancer Consensus Conference

Huge congratulations to @DrMHofman for receiving the prestigious 2025 @TheRACP Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics. https://t.co/6aaxmECgZl

Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with @DrMHofman, @PCF_Science, @gu_onc and our special guest speakers: @mishabeltran, @drlouiseemmett, @EdmondMKwan & @radnucmp 🔬 Live, interactive and FREE‼️ Register now: https://t.co/NFSQHxmRaz

@DrMHofman presents at 2025 PSMA & Beyond Conference @UCLA @UCSF @PCFnews ... Impressive attendance! Thanks to organisers: @thomashopemd @CalaisJeremie @CzerninJohannes @urotoday Don't miss our next webinar: https://t.co/zABXXv5CYP

BREAKING NEWS🎉 @PeterMacRes researchers awarded $21M in @nhmrc funding, including #prostic Director @DrMHofman! Prof. Hofman's research will incorporate new radioactive tumour seeking molecules, whole body scanning and AI for #prostatecancer clinical trials and treatments☢️

We're back! @PeterMacRadOnc @PeterMacCC - Nov 14th and 15th.... save the date!!!! #radonc #radiotherapy

Devaki Surasi presents on combination trials with Lutetium-177 ... So many Aussie trials! @ASCO #GU25 @pros_tic

Ab#17 @ASCO #GU25 by #LouiseEmmett👉 https://t.co/h6Yx0xPpd9👉OS & HRQoL data from ENZA-p (ANZUP 1901) #prostatecancer👉Lu-177 + enza vs enza👉⬆️OS & HRQoL in poor risk mCRPC👇@MartinStockler @OncoAlert @urotoday @PCF_Science

Excited to have @ANZUPtrials #ENZAp #ProstateCancer #pcsm #ClinicalTrial OS and HRQoL data presented at #GU25 this week by the incomparable @drlouiseemmett - don’t miss it!

Thanks to @UniMelb for the Xmas present: promotion to Full Professor. Too many people to thank - my parents & brother, my wife @melkauf2018, many wonderful colleagues & collaborators, industry partners, & all the patients who have selflessly supported #ProstateCancer research 🙏

🎉 Thrilled to announce the promotion of Dr. Arun Azad to PROFESSOR @AzadOncology A leader in uro-oncology, Professor Azad's groundbreaking work in prostate cancer has transformed care globally. Join us in congratulating him! 👏

Congrats Team @pros_tic ! A hyper-productive year. More to come in 2025 with results of VIOLET and AlphaBet clinical trials anticipated. @ButeauJames @LouiseKostos

Michael Hofman (@DrMHofman )‘s top 10 publications from 2024 which ProsTic (@pros_tic) contributed to https://t.co/500FsqcpWj #Cancer #ProstateCancer #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology